Skip to main content
Menu

Posts tagged with "Infectious Diseases"

  • Covid-19

    Regeneron’s Monoclonal Antibody Cocktail in Primates

    I’m very glad to see some data emerging on the monoclonal antibody therapies that have been in the works. Regeneron  and Eli Lilly/Abcellera are two of the front-runners in this field, which could pick up some very much needed slack while the many vaccine trials are going on. And late yesterday a preprint emerged from… Read More
  • Clinical Trials

    Coronavirus Challenges in Primates, Compared

    We have a sudden influx over the last few days of preclinical rhesus challenge studies with various coronavirus vaccines, and it’s only natural to try to compare them. I have worked up a table with all four of the current results and the previously reported SinoVac inactivated virus vaccine, whose rhesus challenge numbers were officially… Read More
  • Cancer

    Bacteria and Colon Cancer

    Let’s catch on some non-coronavirus research today with an interesting approach against a very bad disease, metastatic colon cancer. This new paper (from groups at Virginia Tech and Wake Forest) adds to our understanding of something that’s been noticed for some time: colon cancer tissue is often infected with Fusobacterium nucleatum. T… Read More
  • Clinical Trials

    New Data on the CanSino Vaccine

    And now we have more data on the CanSino vaccine, another adenovirus vector (but this one using Ad5, a much more common one in the human population). Their initial Phase I data are discussed here. So what else do we know now? Well, that one was open label and non-randomized, whereas this one is fully controlled. Read More
  • Clinical Trials

    New Data on the Oxford/AZ Vaccine

    The hype began building late last week around the Oxford vaccine results released today, and I will confess to wondering just what was going on. The British press has a history of going berserk over drug research – I wouldn’t care to count how many times Alzheimer’s “breakthroughs” have hit the headlines over there, an… Read More
  • Clinical Trials

    More Pfizer Phase I Results: Antibodies, Viral Mutations, and T Cells

    Recent posts here have gone into Moderna’s Phase I vaccine data, Pfizer’s Phase I vaccine data, what we don’t know yet about the relationship between T-cells, antibodies, and immunity to the coronavirus, and some new data that are starting to fill in those gaps. This morning comes a new preprint from the Pfizer/BioNTech team that… Read More
  • Covid-19

    New Data on T Cells and the Coronavirus

    Well, I was writing just the other day about what we don’t know about the T-cell response to coronavirus infection, and as of today we know quite a bit more. And from what I can see, we have encouraging news, mixed with some things that we’re going to need to keep an eye on. Here’s… Read More
  • Clinical Trials

    Moderna’s Phase I Data

    Well, it’s finally here – eight weeks to the day after press-releasing some top line results, the full paper is out on the Moderna mRNA vaccine candidate’s Phase I trial. I’m very glad to see it – it’s going to be very important for the full data sets on all the vaccine candidates to be… Read More
  • Clinical Trials

    Pfizer’s Progress

    I wanted to point out an interesting interview given by Pfizer’s CEO Albert Bourla to Time. I have made some pointed remarks about Pfizer over the years, but this is one of the better Q&A pieces like this that I have seen – you’ll see why in some of the answers below. Bourla is actually… Read More
  • Covid-19

    More on T Cells, Antibody Levels, and Our Ignorance

    I wrote here about the reports of rather short antibody persistence in recovering coronavirus patients, and what’s been coming out in the two weeks since then has only made this issue more important. In that post, I was emphasizing that although we can measure antibody levels, we don’t know how well that correlates with exposure… Read More
123...